Mifepristone: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential

Drugs

Volumn 45, Issue 3, 1993, Pages 384-409

  Brogden, Rex N ^a   Goa, Karen L ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIGESTAGEN; GEMEPROST; GLUCOCORTICOID ANTAGONIST; MIFEPRISTONE; ORAL CONTRACEPTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; PROSTAGLANDIN DERIVATIVE;

ABDOMINAL PAIN; CANCER; CUSHING SYNDROME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG THERAPY; DRUG TOLERANCE; ENDOMETRIOSIS; FEMALE; FETUS DEATH; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; LABOR INDUCTION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREGNANCY TERMINATION; PREMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX DILATATION; UTERUS MYOMA;

CONTRACEPTIVES, POSTCOITAL; FEMALE; HUMAN; MIFEPRISTONE; PREGNANCY;

EID: 0027394348     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199345030-00007     Document Type: Article

References (136)

1. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486
2. Activité contragestive de l’association au RU 486 d’une prostaglandine active par voie orale
3. RU 486: an antiprogestin steroid with contraceptive activity in women
4. The new steroid analog RU 486 inhibits glucocorticoid action in man
5. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome
6. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and epostane
7. 1 methyl ester) or the antiprogestogen RU,486
8. Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (Gemeprost)
9. Induction of labour with mifepristone after intrauterine fetal death. Correspondence
10. Induction of labor with mifepristone (RU 486) in intrauterine fetal death
11. Pharmacokinetic study of orally administered RU 486 in non-pregnant women
12. Comparison of different prostaglandin analogues and laminaria for preoperative dilatation of the cervix in the late first-trimester abortion
13. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486
14. Pretreatment of the primigravid uterine cervix with mifepristone 30h prior to termination of pregnancy: a double blind study
15. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone)
16. Variable effects of RU486 on endometrial maintenance in the luteal phase extended by exogenous HCG
17. Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding patterns or ovulation
18. LAte luteal phase administration of RU 486 for three consecutive cucles does not disrupt bleeding patterns or ovulation
19. The prospects of prostaglandins in post conceptional therapy
20. Arret cardio-circulatoire apres administration de l’association mifepristone (Mifegyne) sulprostone (Nalador) pour interruption de grosses-se. Abstract
21. Pharmacokinetics of RU 486
22. Ethinylestradiol and conjugated estrogens as postcoital contraceptives
23. Contragestion with late luteal administration of RU 486 (mifepristone)
24. Labour induction in women at term with mifepristone (RU 486): a double-blind, randomised, placebo-controlled study
25. Transplacental passage of mifepristone. Correspondence
26. RU486: A steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system, at a specific time of day
27. Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle
28. Postcoital contraception with mifepristone
29. Mifepristone(RU 486) compared with high dose estrogen and proges-togen for emergency postcoital treatment
30. Oestradiol applied locally to ripen the unfavourable cervix
31. The use of antiprogestin (RU 486) for termination of second trimester pregnancy
32. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women
33. In vitro Study of the binding of RU 486 and RU 42633 to human serum proteins
34. Predictors of failed attempted abortion with the antiprogestin mifepristone (RU 486)
35. Early abortion with a single dose of the antiprogestin RU-486
36. Prevention of uterine perforation during curettage abortion
37. The role of progesterone receptors in meningioma
38. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
39. Effect of chronic administration of RU486 on thyroid function. Abstract
40. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix
41. Should we use prostaglandins, tents or progesterone antagonists for cervical ripening before first trimester abortion?
42. Successful mifepristone treatment of recurrent, inoperable meningioma
43. Response of meningioma to mifepristone. Abstract
44. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration
45. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans
46. Metabolism and serum binding of RU 486 in women after various single doses
47. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography
48. Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486
49. RU 486 abortions
50. Pre-operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU 486)
51. Mifepristone: separating fact from fiction
52. 1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability
53. The effect of RU 38,486 on progesterone and oestrogen receptor concentrations in the decidua and placenta in early pregnancy
54. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of, pregnancy
55. 2 for an early pregnancy termination
56. Antiprogestins in fertility control: pharmacological and clinical outlines of RU 486
57. Could antiprogesterones be used as alternative cervical ripening agents?
58. Pregnancy interruption with RU 486 in combination with dl-15-methyl-prostaglandin-F2α-methylester: the Chinese experience
59. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man
60. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis
61. Antiprogestins, a new form of endocrine therapy for human breast cancer
62. Termination of very early pregnancy by RU 486 — an antiprogestational compound
63. Pharmacokinetics and metabolism of RU 486
64. Late postcoital treatment against pregnancy with antiprogesterone RU 486
65. The endocrine effects of long-term treatment with mifepristone (RU 486)
66. Mifepristone (RU 486) treatment of meningiomas
67. The effects of RU-38486 on cervical ripening
68. The effects of RU-38486 on cervical ripening
69. Mifepristone or vacuum aspiration in termination of early pregnancy
70. The effects of progesterone blockade in the luteal phase of normal fertile women
71. Normal development after exposure to mifepristone in early pregnancy
72. Termination of early pregnancy through a combination of the antiprogestin and prostaglandin analogue
73. Termination of early pregnancy by a single dose of mifepristone (RU 486), a progesterone antagonist
74. Interruption précoce de la grossesse par un stéroide antiprogestérone: la mifepristone (RU 486)
75. Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose
76. Biochemical Profile of RU 486
77. Automated direct assay system for RU38486, an antiprogesterone-anti-glucocorticoid agent, and its metabolites using high performance liquid chromato-graphy
78. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486
79. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone
80. Uterine activity and decidual prostaglandin production in woman in early pregnancy in response to mifepristone with or without indomethacin in vivo
81. 1 analogue) alone and mifepristone and gemeprost
82. Mifepristone and induction of labour in second half of pregnancy. Correspondence
83. Termination of pregnancy with mifepristone after intra-uterine death
84. Acute effects of progesterone and the antiprogestin RU486 on gonadotropin secretion in the follicular phase of the menstrual cycle
85. Development after exposure to mifepristone in early pregnancy. Correspondence
86. Mifepristone teratogenicity
87. RU 486 (mifepristone) et interruption volontaire ed grossesse pour motif therapeutique an deuxieme et troisieme trimestre
88. Estrogen and progestin receptors in in-tracranial tumors
89. Induced cervical ripening with mifepristone (RU 486) and bioconversion of arachidonic acid in human pregnant uterine cervix in the first trimester
90. Pretreatment with mifeprislone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion
91. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary
92. Blood loss following induction of early abortion using mifepristone (RU486) and a prostaglandin analogue (gemeprost)
93. Induction of early abortion with mifepristone (RU486) and two different doses of prostaglandin pessary (Gemeprost)
94. The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial
95. Effects of the antiprogesterone steroid RU 486 during mid luteal phase in normal women
96. Lack of effect of induced menses on symptoms in women with premenstrual syndrome
97. Measures to prevent cervical injury during suction curettage abortion
98. Clinical trial on termination of early pregnancy with RU 486 in combination with prostaglandin
99. Effects of RU 486 in normal women. Single-dose administration in the mid luteal phase
100. Effects of the antiprogesterone RU 486 in normal women. Administration in the late follicular phase
101. RU 486 (mifepristone): clinical trials in China
102. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue
103. The use of the antiprogestin RU486 (mifepristone)
104. Differences in the binding mechanism of RU486 and progesterone to the progesterone receptor
105. Induction of abortion in early pregnancy with mifepristone
106. Arrêt cardio-circulatoire au cours de l’association mifépri-stone-sulprostone pour interruption de grossesse
107. Effects of the antiprogesterone RU 486 in the early follicular phase of the menstrual cycle
108. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin
109. Oral administration of RU 486 and 9-methylene PGE2 for termination of early pregnancy
110. Termination of early pregnancy with RU 486 (mifepristone) in combination with a prostaglandin analogue (Sulprostone)
111. Contraception with mifepristone. Correspondence
112. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy
113. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy
114. Uses of RU 486 for contragestion: an update
115. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue
116. RU 486
117. 2
118. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy
119. Mifepristone (RU 486) and second-trimester termination. Correspondence
120. Mifepristone (RU 486) for cervical priming prior to surgically induced abortion in the late first trimester
121. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion
122. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486)
123. Postcoital luteal contragestion by an antiprogestin (mifepristone, RU 486) in 62 women
124. Preliminary results with the antiprogestational compound RU-486 (mifepristone) for interruption of early pregnancy
125. Misoprostol for the treatment of peptic ulcer and an-tiinflammatory drug-induced gastroduodenal ulceration
126. Alternative treatments in oral postcoital contraception: interim results
127. Comparision of Yuzpe regimen, dariazol, and mifepristone (RU 486) in oral postcoital contraception
128. Sex hormone receptors in intracranial tumours and normal brain
129. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and proliferative action of estradiol on endometrium in castrated monkeys
130. Randomised comparison of different prostaglandin analogues and laminaria tent for preoperative cervical dilatation
131. The use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration
132. Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone